Literature DB >> 29335263

Exacerbation of psychosis triggered by a synthetic cannabinoid in a 70-year-old woman with Parkinson disease.

Sean J Udow1, Maria Eliza Freitas2, Susan H Fox2, Anthony E Lang2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29335263      PMCID： PMC5770252          DOI： 10.1503/cmaj.170361

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  11 in total

1.  Physiologic disposition of nabilone, a cannabinol derivative, in man.

Authors:  A Rubin; L Lemberger; P Warrick; R E Crabtree; H Sullivan; H Rowe; B D Obermeyer
Journal:  Clin Pharmacol Ther       Date:  1977-07       Impact factor: 6.875

Review 2.  Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology.

Authors:  Barbara S Koppel; John C M Brust; Terry Fife; Jeff Bronstein; Sarah Youssof; Gary Gronseth; David Gloss
Journal:  Neurology       Date:  2014-04-29       Impact factor: 9.910

3.  Behavioral effects of levodopa.

Authors:  Isabelle Beaulieu-Boire; Anthony E Lang
Journal:  Mov Disord       Date:  2014-12-09       Impact factor: 10.338

Review 4.  The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.

Authors:  R G Pertwee
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

Review 5.  The therapeutic potential of cannabinoids for movement disorders.

Authors:  Benzi Kluger; Piera Triolo; Wallace Jones; Joseph Jankovic
Journal:  Mov Disord       Date:  2015-02-04       Impact factor: 10.338

6.  Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology.

Authors:  Sagnik Bhattacharyya; Paul D Morrison; Paolo Fusar-Poli; Rocio Martin-Santos; Stefan Borgwardt; Toby Winton-Brown; Chiara Nosarti; Colin M O' Carroll; Marc Seal; Paul Allen; Mitul A Mehta; James M Stone; Nigel Tunstall; Vincent Giampietro; Shitij Kapur; Robin M Murray; Antonio W Zuardi; José A Crippa; Zerrin Atakan; Philip K McGuire
Journal:  Neuropsychopharmacology       Date:  2009-11-18       Impact factor: 7.853

Review 7.  Adverse health effects of marijuana use.

Authors:  Nora D Volkow; Ruben D Baler; Wilson M Compton; Susan R B Weiss
Journal:  N Engl J Med       Date:  2014-06-05       Impact factor: 91.245

Review 8.  The psychosis spectrum in Parkinson disease.

Authors:  Dominic H Ffytche; Byron Creese; Marios Politis; K Ray Chaudhuri; Daniel Weintraub; Clive Ballard; Dag Aarsland
Journal:  Nat Rev Neurol       Date:  2017-01-20       Impact factor: 42.937

Review 9.  Effects of Cannabis Use on Human Behavior, Including Cognition, Motivation, and Psychosis: A Review.

Authors:  Nora D Volkow; James M Swanson; A Eden Evins; Lynn E DeLisi; Madeline H Meier; Raul Gonzalez; Michael A P Bloomfield; H Valerie Curran; Ruben Baler
Journal:  JAMA Psychiatry       Date:  2016-03       Impact factor: 21.596

Review 10.  'Under pressure': is there a link between orthostatic hypotension and cognitive impairment in α-synucleinopathies?

Authors:  Sean J Udow; Andrew D Robertson; Bradley J MacIntosh; Alberto J Espay; James B Rowe; Anthony E Lang; Mario Masellis
Journal:  J Neurol Neurosurg Psychiatry       Date:  2016-09-09       Impact factor: 10.154
View more
  2 in total

1.  Safety and Tolerability of Natural and Synthetic Cannabinoids in Older Adults: A Systematic Review and Meta-Analysis of Open-Label Trials and Observational Studies.

Authors:  Latha Velayudhan; Sagnik Bhattacharyya; Sara Pisani; Katie McGoohan
Journal:  Drugs Aging       Date:  2021-07-08       Impact factor: 3.923

Review 2.  Neuroprotection or Neurotoxicity of Illicit Drugs on Parkinson's Disease.

Authors:  Carla Ferreira; Catarina Almeida; Sandra Tenreiro; Alexandre Quintas
Journal:  Life (Basel)       Date:  2020-06-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.